Suppr超能文献

小脑多巴胺 D3 受体在调节大鼠探索性运动和僵住症中的作用。

Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.

机构信息

Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.

Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:157-62. doi: 10.1016/j.pnpbp.2013.12.013. Epub 2013 Dec 22.

Abstract

Dopamine D(3) receptors are highly expressed in the cerebellum; however, their pathophysiological functions are not fully understood. Here, we conducted microinjection studies to clarify the role of cerebellar D(3) receptors in modulating locomotion and cataleptogenicity in rats. Microinjection of the preferential D(3) agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) into lobe 9 of the cerebellum significantly reduced spontaneous locomotor activity with a U-shaped dose-response curve. The intracerebellar microinjection of 7-OH-DPAT did not elicit catalepsy by itself, but markedly potentiated catalepsy induction with a low dose (0.3mg/kg) of haloperidol. The catalepsy enhancement by 7-OH-DPAT occurred in a dose-dependent manner and was not associated with the locomotor inhibition. U-99194A (a selective D(3) antagonist) or AD-6048 (a preferential D(3) vs. D(2) antagonist) antagonized both the catalepsy enhancement and the locomotor inhibition with 7-OH-DPAT. In addition, U-99194A and AD-6048 per se significantly alleviated catalepsy induced by a high dose (0.5mg/kg) of haloperidol. Furthermore, microinjection of 7-OH-DPAT into the nucleus accumbens or the dorsolateral striatum neither affected spontaneous locomotor activity nor haloperidol (0.3mg/kg)-induced catalepsy. The present results illustrate for the first time the role of cerebellar D(3) receptors in modulating cataleptogenicity of antipsychotic agents, implying that blockade of cerebellar D(3) receptors contributes to the reduction of extrapyramidal side effects.

摘要

多巴胺 D3 受体在小脑内高度表达;然而,其生理病理学功能尚未完全阐明。在这里,我们进行了微注射研究,以阐明小脑 D3 受体在调节大鼠运动和僵住症中的作用。将优先 D3 激动剂 7-羟基-N,N-二正丙基-2-氨基四氢萘(7-OH-DPAT)微注射到小脑叶 9 中,显著减少了自发性运动活动,呈现出 U 形剂量反应曲线。7-OH-DPAT 本身不会引起僵住症,但会显著增强低剂量(0.3mg/kg)氟哌啶醇引起的僵住症。7-OH-DPAT 的僵住症增强呈剂量依赖性,与运动抑制无关。U-99194A(一种选择性 D3 拮抗剂)或 AD-6048(一种优先 D3 与 D2 拮抗剂)拮抗 7-OH-DPAT 引起的僵住症增强和运动抑制。此外,U-99194A 和 AD-6048 本身也显著缓解了高剂量(0.5mg/kg)氟哌啶醇引起的僵住症。此外,将 7-OH-DPAT 微注射到伏隔核或背外侧纹状体既不影响自发运动活动,也不影响氟哌啶醇(0.3mg/kg)引起的僵住症。本研究结果首次阐明了小脑 D3 受体在调节抗精神病药物僵住症中的作用,表明阻断小脑 D3 受体有助于减少锥体外系副作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验